Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 624

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 3
Chunk 624
---
 as we are an accelerated filer or large accelerated filer.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the year ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. OTHER INFORMATION.

None of the Company's directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

Not applicable.

50

PART III

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

Directors

Our directors and their ages as of the date of this filing are set forth below. Each director is elected annually to serve until the next annual meeting of shareholders, or until his or her successor is duly elected.

			Name 

			Age 

			Position(s) Held

			Director Since

			Joan Chypyha (1) (2)

			59

			Director

			May 23, 2023

			David Liu (2) (4)

			40

			Director

			February 12, 2025

			Sean MacDonald 

			49

			Director

			June 7, 2019

			Patrick Marshall (1) (3)

			54

			Director

			May 23, 2023

			Pardeep Nijhawan, MD

			55

			Director and Chief Executive Officer

			June 7, 2019

			Charles Olson, DSc (2) (3)

			68

			Director

			May 23, 2023

			Carlo Sistilli, CPA, CMA (1)

			69

			Chairman of the Board of Directors

			June 7, 2019

			(1)
			
			Member of Audit Committee.

			(2)
			
			Member of Compensation Committee.

			(3)